Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2017
18th World Conference on Lung Cancer
Access to all presentations that occur during the 18th World Conference on Lung Cancer in Yokohama, Japan
Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Download PDF of the Conference Program: Click Here.
Presentations will be available 24 hours after their live presentation time
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
-
+
P1.03 - Chemotherapy/Targeted Therapy
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 53
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.03-001 - Verification and Implementation of the VENTANA Anti-ALK D5F3 Antibody in Detecting ALK Rearrangement in NSCLC
09:30 - 09:30 | Author(s): N. Nadira
- Abstract
Loading... -
+
P1.03-002 - Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-Positive Advanced NSCLC Patient
09:30 - 09:30 | Presenter: Shaoyu Yang
- Abstract
Loading... -
+
P1.03-003 - Clinical Implications of an Analysis of Crizotinib Pharmacokinetics Co-Administered with Dexamethasone in Patients with NSCLC
09:30 - 09:30 | Presenter: Swan Lin
- Abstract
Loading... -
+
P1.03-004 - Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status
09:30 - 09:30 | Presenter: Hirotsugu Kenmotsu
- Abstract
Loading... -
+
P1.03-005 - Phase 2 Study of Ceritinib in Patients with ALK+ NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9
09:30 - 09:30 | Presenter: Hidehito Horinouchi
- Abstract
Loading... -
+
P1.03-006 - Clinicopathological Features and Poor Outcome for ALK Inhibitors of Squamous Cell Lung Cancer with ALK-Rearrangement
09:30 - 09:30 | Presenter: Hiroaki Motomura
- Abstract
Loading... -
+
P1.03-007 - A Real-World Study of Clinicopathological Characteristics and Survival Outcome in Advanced ALK-Positive Non-Small-Cell Lung Cancer
09:30 - 09:30 | Author(s): Y. Jin
- Abstract
Loading... -
+
P1.03-008 - Analysis of Data on Interstitial Lung Disease Onset and Its Risk Following Treatment of ALK-positive NSCLC with Xalkori
09:30 - 09:30 | Presenter: Akihiko Gemma
- Abstract
Loading... -
+
P1.03-009 - A Lung Adenocarcinoma with a STRN-ALK Rearrangement Was Poorly Responsive to Alectinib Treatment
09:30 - 09:30 | Presenter: Yuko Iida
- Abstract
Loading... -
+
P1.03-010 - Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Reina Imase
- Abstract
Loading... -
+
P1.03-011 - Clinical Outcomes Correlated with Percentage of Positive Anaplastic-Lymphoma Kinase Cells Tested by FISH Analysis in NSCLC.
09:30 - 09:30 | Presenter: Katy Louise Clarke
- Abstract
Loading... -
+
P1.03-012 - Using Computational Modeling to Simulate Clinical Response of ALK Inhibitors to G1202R ALK and Possible Mechanisms of Resistance
09:30 - 09:30 | Presenter: Chien-Ting Liu
- Abstract
Loading... -
+
P1.03-013 - Monitoring of ALK Fusions and Mutations in Advanced ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
09:30 - 09:30 | Presenter: Laura Mezquita
- Abstract
Loading... -
+
P1.03-014 - Saline Alone vs Saline plus Mannitol Hydration for the Prevention of Acute Cisplatin Nephrotoxicity: A Randomized Trial
09:30 - 09:30 | Presenter: Wilfred Dela Cruz
- Abstract
Loading... -
+
P1.03-015 - The Relationship between the UGT1A1*27 and UGT1A1*7 Genetic Polymorphisms and Irinotecan-Related Toxicities in Patients with Lung Cancer
09:30 - 09:30 | Presenter: Minoru Fukuda
- Abstract
Loading... -
+
P1.03-016 - Video-Thoracoscopic Pulmonary Resection Avoids Delay and Increase Adjuvant Chemotherapy Compliance for Non-Small Cell Lung Carcinoma
09:30 - 09:30 | Presenter: Ak?n Ozturk
- Abstract
Loading... -
+
P1.03-017 - Benzyl Isothiocyanate Induces Protective Autophagy in Human Lung Cancer Cells through Endoplasmic Reticulum Stress-Mediated Mechanism
09:30 - 09:30 | Author(s): Q. Zhang
- Abstract
Loading... -
+
P1.03-018 - Effectiveness of Supportive Care Drugs in Lung Cancer Patients Undergoing 1st Line Chemotherapy in a Resource Limited Setting
09:30 - 09:30 | Presenter: Digambar Behera
- Abstract
Loading... -
+
P1.03-019 - Sophoridine Inhibits Lung Cancer Cell Proliferation through Activating Hippo Signaling and P53 Pathway
09:30 - 09:30 | Presenter: Jiangping Xiong
- Abstract
Loading... -
+
P1.03-020 - Detection of Hypoxia Using EF5 PET/CT in 10 Patients with Advanced NSCLC Receiving Chemotherapy with and without Bevacizumab
09:30 - 09:30 | Presenter: Frederic Lacroix-Poisson
- Abstract
Loading... -
+
P1.03-021 - A Prospective Observational Study to Evaluate Incidence of Thromboembolic Events during Platinum Based Chemotherapy in Lung Cancer
09:30 - 09:30 | Presenter: Vikas Talreja
- Abstract
Loading... -
+
P1.03-022 - A Phase 1B Study of TRC105 in Combination with Paclitaxel/Carboplatin and Bevacizumab in Patients with Stage 4 Non-Squamous Cell Lung Cancer
09:30 - 09:30 | Author(s): Francisco Robert
- Abstract
Loading... -
+
P1.03-023 - The Real-World Practice of Bevacizumab Plus Chemotherapy in Stage IV Lung Adenocarcinoma: A Single Institute Experience
09:30 - 09:30 | Presenter: Yen-Hao Chen
- Abstract
Loading... -
+
P1.03-024 - Efficacy of Carboplatin-Vinorelbine in Advanced NSCLC Patients at Persahabatan Hospital, Jakarta - Indonesia
09:30 - 09:30 | Presenter: Putu Ayu Diah
- Abstract
Loading... -
+
P1.03-025 - Combination Therapy with Carboplatin and Hyperoxia Synergistically Enhances Suppression of Benzo[a]Pyrene Induced Lung Cancer
09:30 - 09:30 | Presenter: Sang Haak Lee
- Abstract
Loading... -
+
P1.03-026 - Interim Results of a Phase I Study of Nivolumab plus Nab-Paclitaxel/Carboplatin in Patients with NSCLC
09:30 - 09:30 | Presenter: Jonathan W. Goldman
- Abstract
Loading... -
+
P1.03-027 - Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR Study)
09:30 - 09:30 | Presenter: Shinji Atagi
- Abstract
Loading... -
+
P1.03-028 - A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Untreated Stage IV Squamous Cell Lung Cancers
09:30 - 09:30 | Presenter: Paul K. Paik
- Abstract
Loading... -
+
P1.03-029 - Study of Plasma Homocysteine as a Marker of Toxicity and Depression in Patients Treated with Pemetrexed-Based Chemotherapy
09:30 - 09:30 | Author(s): A.R. Minchom
- Abstract
Loading... -
+
P1.03-030 - Prognostic Impact of the Presence of COPD in Patients with NSCLC under Conventional Systemic Chemotherapy
09:30 - 09:30 | Presenter: Jin Woo Kim
- Abstract
Loading... -
+
P1.03-031 - Adherence and Feasibility of 2 Treatment Schedules of S-1 as Adjuvant Chemotherapy in Completely Resected Lung Cancer
09:30 - 09:30 | Presenter: Takaharu Kiribayashi
- Abstract
Loading... -
+
P1.03-032 - Observation of Durative Infusion Endostar Combined with Chemotherapy Within Vascular Normalization Period in Advanced NSCLC
09:30 - 09:30 | Author(s): Qing Zhou
- Abstract
Loading... -
+
P1.03-033 - Long-Term Outcome of Histoculture Drug Response Assay Guided Adjuvant Chemotherapy in Patients with Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Yoshimitsu Hirai
- Abstract
Loading... -
+
P1.03-034 - Therapeutic Effect of Novel Leucyl-tRNA Synthetase Inhibitor, B1206, in Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Eun Young Kim
- Abstract
Loading... -
+
P1.03-035 - Efficacy of Nintedanib and Docetaxel in Combination with the Nutraceutical Use of Silibinin in Advanced NSCLC
09:30 - 09:30 | Presenter: Joaquim Bosch Barrera
- Abstract
Loading... -
+
P1.03-036 - Adjuvant Chemotherapy with Uracil-Tegafur for Pathological T1aN0M0 Lung Adenocarcinoma with Lymphatic Vessel Invasion
09:30 - 09:30 | Presenter: Yoshitaka Kitamura
- Abstract
Loading... -
+
P1.03-037 - A Phase II Study of Adjuvant Chemotherapy with Docetaxel plus Nedaplatin for Completely Resected Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Koji Teramoto
- Abstract
Loading... -
+
P1.03-038 - A Phase I Trial of Afatinib and Bevacizumab in Untreated Patients with Advanced NSCLC Harboring EGFR-Mutations: OLCSG1404
09:30 - 09:30 | Presenter: Shoichi Kuyama
- Abstract
Loading... -
+
P1.03-039 - Therapeutic Inhibition of the Cancer Stem Cell Marker, ALDH1, a Promising Mechanism by Which Cisplatin Sensitivity Can Be Restored in NSCLC
09:30 - 09:30 | Author(s): L. Mac Donagh
- Abstract
Loading... -
+
P1.03-040 - Smokers Having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment - Single Center Experience
09:30 - 09:30 | Author(s): O. Ercelep
- Abstract
Loading... -
+
P1.03-041 - Exploitation of the Cancer Stem Cell Marker ALDH1 Within the Vitamin a/Retinoic Acid Axis Promotes Re-Sensitisation of Cisplatin Resistant NSCLC
09:30 - 09:30 | Author(s): L. Mac Donagh
- Abstract
Loading... -
+
P1.03-042 - BBI608, a Small Molecule Stemness Inhibitor, Circumvents Cisplatin Resistance in NSCLC
09:30 - 09:30 | Author(s): L. Mac Donagh
- Abstract
Loading... -
+
P1.03-043 - 30-Day Mortality Following Systemic Anti-Cancer Treatment for NSCLC at a Single Canadian Cancer Centre
09:30 - 09:30 | Author(s): A.J.W. Gibson
- Abstract
Loading... -
+
P1.03-044 - Exploratory Analysis of Lung Cancer Patients in a Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine
09:30 - 09:30 | Presenter: Lyudmila Bazhenova
- Abstract
Loading... -
+
P1.03-045 - HER-2 Mutation Is Not a Prognostic Factor Treated with First-Line Chemotherapy in NSCLC Patients
09:30 - 09:30 | Author(s): C. Zhao
- Abstract
Loading... -
+
P1.03-046 - A Retrospective Analysis of Correlation Between Cytokines in TME and Therapeutic Effect of Advanced Lung Cancer Chemotherapy in China
09:30 - 09:30 | Author(s): J. Shen
- Abstract
Loading... -
+
P1.03-047 - Carboplatin/ Weekly Nab-PTX in Elderly Patients with Previously Untreated Advanced Squamous NSCLC Selected Based on MNA-SF
09:30 - 09:30 | Presenter: So Takata
- Abstract
Loading... -
+
P1.03-048 - miR-34a and the Micromanagement of Cancer Stemness and Resistance in NSCLC. Does It Hold Therapeutic Benefit?
09:30 - 09:30 | Author(s): L. Mac Donagh
- Abstract
Loading... -
+
P1.03-049 - Phase II Study of S-1 plus Bevacizumab Combination Therapy for Patients Previously Treated for Non-Squamous Non–Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Kentaro Masuhiro
- Abstract
Loading... -
+
P1.03-050 - Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial
09:30 - 09:30 | Presenter: David S Ettinger
- Abstract
Loading... -
+
P1.03-051 - Development of a Novel Microfluidic Device for Studying the Chemotaxis Mechanism of Bacterial Cancer Targeting
09:30 - 09:30 | Author(s): J. Song
- Abstract
Loading... -
+
P1.03-052 - Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism
09:30 - 09:30 | Presenter: Yayi He
- Abstract
Loading... -
+
P1.03-053 - Taiwan Real Word Efficacy of 1st Line EGFR TKIs Treatment in EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Chih-Yen Tu
- Abstract
Loading...
-
+
P1.04 - Clinical Design, Statistics and Clinical Trials
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 13
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.04-001 - Osimertinib with Ramucirumab or Necitumumab in Advanced T790M-positive EGFR-Mutant NSCLC: Preliminary Ph1 Study Results
09:30 - 09:30 | Presenter: Helena Yu
- Abstract
Loading... -
+
P1.04-002 - Tolerability of Osimertinib and Its Impact on Quality of Life in Advanced Non-Small Cell Lung Cancer Patients: The ARPA Study
09:30 - 09:30 | Presenter: Enrica Capelletto
- Abstract
Loading... -
+
P1.04-003 - The International Lung Screen Trial: A Multi-Centre Study to Evaluate LDCT Screening Selection Criteria and Nodule Management
09:30 - 09:30 | Presenter: Kuan Pin Lim
- Abstract
Loading... -
+
P1.04-004 - Phase I/Ib Study of Nivolumab and Veliparib in Advanced Solid Tumors and Lymphoma with and without Alterations in Selected DNA Repair Genes
09:30 - 09:30 | Author(s): Y.K. Chae
- Abstract
Loading... -
+
P1.04-005 - Phase 2 Study of Nivolumab and Metformin in Advanced Non-Small Cell Lung Cancer with and without Prior Treatment with PD-1/PD-L1 Inhibitors
09:30 - 09:30 | Author(s): Y.K. Chae
- Abstract
Loading... -
+
P1.04-006 - Rovalpituzumab Tesirine vs Topotecan in Patients with Advanced Small Cell Lung Cancer Following 1st Line Chemotherapy
09:30 - 09:30 | Presenter: Philip Komarnitsky
- Abstract
Loading... -
+
P1.04-007 - Rovalpituzumab Tesirine Maintenance Therapy Following 1st Line Platinum-Based Chemotherapy Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Philip Komarnitsky
- Abstract
Loading... -
+
P1.04-008 - POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC
09:30 - 09:30 | Presenter: Tony SK Mok
- Abstract
Loading... -
+
P1.04-009 - The First Study of BBSKE in Heavy Treated Advanced EGFR Wild Type and ALK Negative, Trxr1 High Expression NSCLC Patients.
09:30 - 09:30 | Presenter: Yongchang Zhang
- Abstract
Loading... -
+
P1.04-010 - CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia
09:30 - 09:30 | Presenter: Shun Lu
- Abstract
Loading... -
+
P1.04-011 - Development of Novel Blood-Based Biomarker Assays in 1L Advanced/ Metastatic NSCLC: Blood First Assay Screening Trial (BFAST)
09:30 - 09:30 | Presenter: Tony SK Mok
- Abstract
Loading... -
+
P1.04-012 - A Phase 1b Dose-Escalation Study of TRC105 in Combination with Nivolumab in Patients with Metastatic Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): Francisco Robert
- Abstract
Loading... -
+
P1.04-013 - Phase 1b Multi-Indication Study of the Antibody Drug Conjugate Anetumab Ravtansine in Patients with Mesothelin-Expressing Advanced or Recurrent Malignancies
09:30 - 09:30 | Presenter: Alex Adjei
- Abstract
Loading...
-
+
P1.05 - Early Stage NSCLC
- Type: Poster Session with Presenters Present
- Track: Early Stage NSCLC
- Presentations: 26
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.05-001 - Microwave Ablation plus Recombinant Human Endostatin (Endostar) versus Microwave Ablation Alone in Inoperable Stage I Non Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Guanghui Huang
- Abstract
Loading... -
+
P1.05-002 - Characteristics and Prognosis of Ground Glass Opacity Predominant Primary Lung Cancer Larger Than 3.0 Cm on Thin-Section Computed Tomography
09:30 - 09:30 | Presenter: Shigeki Suzuki
- Abstract
Loading... -
+
P1.05-003 - Impact of Coexisting Pulmonary Diseases on Oncological Outcomes of Patients with pStage I Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Hiroyuki Tao
- Abstract
Loading... -
+
P1.05-004 - Adenocarcinoma Subtyping of Early Stage Lung Cancer in a Danish Cohort
09:30 - 09:30 | Presenter: Petrine laier Sonne
- Abstract
Loading... -
+
P1.05-005 - Percutaneous Cryoablation for Lung Cancer Patients with Idiopathic Pulmonary Fibrosis
09:30 - 09:30 | Presenter: Takashi Ohtsuka
- Abstract
Loading... -
+
P1.05-006 - Clinicopathological Features of Small-Sized Peripheral Squamous Cell Lung Cancer
09:30 - 09:30 | Presenter: Takayuki Kosaka
- Abstract
Loading... -
+
P1.05-007 - A Retrospective Study to Compare Resection Rate and Survival Rate in Operable Stage I to III NSCLC After Introduction of Lung Cancer MDT
09:30 - 09:30 | Presenter: Ying Ying Sum
- Abstract
Loading... -
+
P1.05-008 - A Comparison of the Imaging Features of Early Stage Primary Lung Cancer in Patients Treated with Surgery, SABR and Microwave Ablation
09:30 - 09:30 | Presenter: Ambika Talwar
- Abstract
Loading... -
+
P1.05-009 - Analysis of Postoperative Prognosis in Terms of the Difference Between the Invasive Growth Area and the Total Tumor Diameter
09:30 - 09:30 | Presenter: Masaya Yotsukura
- Abstract
Loading... -
+
P1.05-010 - Curative Treatment Rates for Patients Diagnosed with Early Stage Non-Small Cell Lung Cancer (NSCLC) in England
09:30 - 09:30 | Author(s): A. Khakwani
- Abstract
Loading... -
+
P1.05-011 - Comparison of Tumor Measurement Methods in Patients with Clinical Stage IA Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Takuya Nagashima
- Abstract
Loading... -
+
P1.05-012 - Treatment Planning in Non-Small Cell Lung Cancer Shows Variable Utilization of Multidisciplinary Tumor Board
09:30 - 09:30 | Presenter: Joshua Robert Rayburn
- Abstract
Loading... -
+
P1.05-013 - Induction Chemoradiation Is Associated with Improved Survival in Resected Non-Pancoast Lung Cancer with Chest Wall Invasion
09:30 - 09:30 | Author(s): J.A. Munoz-Largacha
- Abstract
Loading... -
+
P1.05-014 - Efficacy of Adjuvant Chemotherapy for Completely Resected Stage IB Non-Small Cell Lung Cancer
09:30 - 09:30 | Author(s): Min Kwang Byun
- Abstract
Loading... -
+
P1.05-015 - Major Pathological Response as a Predictive Value of Survival in Early-Stage NSCLC After Chemotherapy: Cohort of NATCH Phase III Trial
09:30 - 09:30 | Presenter: Enric Carcereny
- Abstract
Loading... -
+
P1.05-016 - The Prognosticator in Synchronous Multiple Primary Lung Cancer: A Comprehensive Analysis of 438 Cases
09:30 - 09:30 | Presenter: Yi Liu
- Abstract
Loading... -
+
P1.05-017 - Prognostic Significance of Preoperative Plasma D-Dimer Level in Patients with Surgically Resected Clinical Stage I Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Kaoru Kaseda
- Abstract
Loading... -
+
P1.05-018 - Prognostic Impact of Tumor Shadow Disappearance Rate in Patients with Clinical IA Lung Adenocarcinoma
09:30 - 09:30 | Presenter: Joji Samejima
- Abstract
Loading... -
+
P1.05-019 - Effects of Tumor Stroma and Inflammation on Survival of Stage I-IIp Lung Cancer
09:30 - 09:30 | Author(s): L. Millares
- Abstract
Loading... -
+
P1.05-020 - Clues of Stromal Invasion of Pulmonary Adenocarcinoma on CT, Focusing on Cicatricial Change
09:30 - 09:30 | Presenter: Ye Kyeong Jun
- Abstract
Loading... -
+
P1.05-021 - Are Prognostic Factors Different from That Which Predicts Recurrence in Completely Resected Pathological Stage IB Adenocarcinoma?
09:30 - 09:30 | Presenter: Hiroyuki Ito
- Abstract
Loading... -
+
P1.05-022 - Association Between Neutrophil/Lymphocyte Ratio and Lymphocyte/Monocyte Ratio with Disease Free Survival in Operated NSCLC Patients in Peru
09:30 - 09:30 | Presenter: Rodrigo Motta
- Abstract
Loading... -
+
P1.05-022a - Positive Pleural Lavage Cytology Is the Independent Prognostic Factor in Lung Cancer Patients with Pathological Stage I Disease
09:30 - 09:30 | Presenter: Tomoko So
- Abstract
No abstract available for this presentation
-
+
P1.05-022b - Identifying Novel Markers of Early Stage Lung Cancer Using a CRISPR/Cas9 Mouse Model
09:30 - 09:30 | Presenter: Paola A Marignani
- Abstract
Loading... -
+
P1.05-022c - Screening for Psychosocial Distress in Lung Cancer: Defining the Unmet Gaps
09:30 - 09:30 | Presenter: Rob Stirling
- Abstract
Loading... -
+
P1.05-022d - Lung Cancer in the Innocent Isn't so Innocent
09:30 - 09:30 | Author(s): U. Ahmad
- Abstract
Loading...
-
+
P1.06 - Epidemiology/Primary Prevention/Tobacco Control and Cessation
- Type: Poster Session with Presenters Present
- Track: Epidemiology/Primary Prevention/Tobacco Control and Cessation
- Presentations: 24
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.06-001 - Does Access to Private Health Care Influence Potential Lung Cancer Cure Rates?
09:30 - 09:30 | Presenter: Thadathilankal Jess John
- Abstract
Loading... -
+
P1.06-002 - The Role of Comorbidity in the Management and Prognosis in Nonsmall Cell Lung Cancer: A Population-Based Study
09:30 - 09:30 | Presenter: Jonas Nilsson
- Abstract
Loading... -
+
P1.06-003 - Preoperative Physical Function and Activity in Elderly Lung Cancer Patients Compared to General Elderly
09:30 - 09:30 | Presenter: Sunga Kong
- Abstract
Loading... -
+
P1.06-004 - Occurrence of Lung Cancer among Young Patients Below the Age of 50 – A Retrospective Analysis
09:30 - 09:30 | Presenter: Anna Maria Romaszko-Wojtowicz
- Abstract
Loading... -
+
P1.06-005 - Sex-Based Disparities in NSCLC: An Evidence-Based Study
09:30 - 09:30 | Presenter: Noor Asaad Alsaadoun
- Abstract
Loading... -
+
P1.06-006 - Survival Benefits and Associated Prognostic Factors among Young NSCLC Patients
09:30 - 09:30 | Author(s): A. D'Silva
- Abstract
Loading... -
+
P1.06-007 - EGFR Status Evaluation and Epidemiological Profile in Patients with NSCLC in a Brazilian Public Health Instituition
09:30 - 09:30 | Author(s): C.D.S.M. Emerich
- Abstract
Loading... -
+
P1.06-008 - Prevalence of Lung Cancer in Patients with Interstitial Lung Disease is Higher than in those with Chronic Obstructive Pulmonary Disease
09:30 - 09:30 | Presenter: Wonil Choi
- Abstract
Loading... -
+
P1.06-009 - Barriers to Clinical Trial Participation in Lung Cancer Patients, a Single Institution Experience
09:30 - 09:30 | Author(s): C.L. Geiger
- Abstract
Loading... -
+
P1.06-010 - Interaction between Treatment Delivery Delay and Stage on the Mortality from Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Fernando Conrado Abrão
- Abstract
Loading... -
+
P1.06-011 - Hyponatremia - Evaluation of Prevalence in Hospitalized Lung Cancer Patients and Its Prognostic Significance
09:30 - 09:30 | Presenter: Sharif Ahmed
- Abstract
Loading... -
+
P1.06-012 - Non-Small Cell Lung Cancer (NSCLC) Patient Characteristics and Clinical Care Insights in Sweden: The SCAN-LEAF Study
09:30 - 09:30 | Presenter: Martin Sandelin
- Abstract
Loading... -
+
P1.06-013 - Latent Tuberculosis in Newly Diagnosed Lung Cancer Patients. An Spanish Prospective Study
09:30 - 09:30 | Author(s): E. Martinez Moreno
- Abstract
Loading... -
+
P1.06-014 - Higher Body Mass Index Prolongs Survival Time in Non-Small Cell Lung Cancer with Good Performance Status
09:30 - 09:30 | Presenter: Tomohiro Suzumura
- Abstract
Loading... -
+
P1.06-015 - Analysis of Relationship Between Non-Small Cell Lung Cancer and Nicotine Dependence
09:30 - 09:30 | Presenter: Yoon Ho Ko
- Abstract
Loading... -
+
P1.06-016 - Route to Lung Cancer Diagnosis in the UK: How Does This Affect Patient Outcome?
09:30 - 09:30 | Presenter: Sher May Ng
- Abstract
Loading... -
+
P1.06-017 - Lung Cancer Detection Rates for National Comprehensive Cancer Network Group 2 High Risk Individuals
09:30 - 09:30 | Presenter: Andrea Katalin Borondy Kitts
- Abstract
Loading... -
+
P1.06-018 - EGFR Mutations and ALK Gene Rearrangements: Changing Patterns of Molecular Testing in Brazil
09:30 - 09:30 | Author(s): S. Palacio
- Abstract
Loading... -
+
P1.06-019 - The Association Between HPV Presence and EGFR Mutations in Asian Patients with NSCLC: A Meta-Analysis
09:30 - 09:30 | Presenter: Hengrui Liang
- Abstract
Loading... -
+
P1.06-020 - Unequal Access to Health Care System Have a Higher Impact in Upgrading Staging for 8th TNM Ed
09:30 - 09:30 | Presenter: Maria Teresa Ruiz Tsukazan
- Abstract
Loading... -
+
P1.06-021 - Lung Cancer Among Women Assisted in an Argentinean University Institution
09:30 - 09:30 | Presenter: Carolina Gabay
- Abstract
Loading... -
+
P1.06-022 - Prognostic Value of NLR in Overall Survival of Patients with Advanced Lung Cancer
09:30 - 09:30 | Presenter: Claudio Flores
- Abstract
Loading... -
+
P1.06-023 - Spatio-Temporal Distribution of Lung Cancer Mortality Rate in Peru: 2005-2014
09:30 - 09:30 | Presenter: Claudio J. Flores
- Abstract
Loading... -
+
P1.06-024 - Outcome of Non-Small Cell Lung Cancer Patients Treated in the Private Health Care in Brazil
09:30 - 09:30 | Author(s): Clarissa Baldotto
- Abstract
Loading...
-
+
P1.07 - Immunology and Immunotherapy
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 48
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.07-001 - Clinical Value of Expression of PD-L1 and CD8 of 58 Cases with NSCLC
09:30 - 09:30 | Presenter: Hongnian Wu
- Abstract
Loading... -
+
P1.07-002 - The Expression of PD-L1 Protein as a Prognostic Factor in Lung Squamous Cell Carcinoma
09:30 - 09:30 | Presenter: Kazuki Takada
- Abstract
Loading... -
+
P1.07-003 - Cytolitic Tests with Hyperimmune Patient Sera Is a Good Prognostic Tool in Racotumomab Immunotherapy in Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Necdet Ismail Hakk? Uskent
- Abstract
Loading... -
+
P1.07-004 - Predictive Biomarkers of Response to Nivolumab in Non–Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study
09:30 - 09:30 | Presenter: Yuki Kataoka
- Abstract
Loading... -
+
P1.07-005 - A Systematic and Genome-Wide Correlation Analysis of PD-L1 Expression and Common NSCLC Driver Genes
09:30 - 09:30 | Presenter: Xiaoshun Shi
- Abstract
Loading... -
+
P1.07-006 - Altered Expression of Programmed Death-1 Receptor (PD-1) and Its Ligand PD-L1, PD-L2 after Neo-Adjuvant Chemotherapy in Lung Cancer
09:30 - 09:30 | Presenter: Wenyu Sun
- Abstract
Loading... -
+
P1.07-007 - Interleukin-17A Promotes Lung Tumor Progression Through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
09:30 - 09:30 | Presenter: Esra A Akbay
- Abstract
Loading... -
+
P1.07-008 - Microbiome & Immunotherapy: Antibiotic Use Is Associated with Inferior Survival for Lung Cancer Patients Receiving PD-1 Inhibitors
09:30 - 09:30 | Presenter: Jonathan R Thompson
- Abstract
Loading... -
+
P1.07-009 - PD-L1 Expression in Circulating Tumor Cells and Response to PD-1 Inhibitor Treatment in Non-Small Cell Lung Cancer Patients
09:30 - 09:30 | Presenter: Nicolas Guibert
- Abstract
Loading... -
+
P1.07-010 - Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
09:30 - 09:30 | Presenter: Junko Tanizaki
- Abstract
Loading... -
+
P1.07-011 - PD-L1 Expression and CD8+ T Cell Infiltration Associate with the Prognosis of Pulmonary Neuroendocrine Tumor
09:30 - 09:30 | Presenter: Haiyue Wang
- Abstract
Loading... -
+
P1.07-012 - Prediction Sensitivity of PD-1 Checkpoint Blockade Using Pathological Tissues Specimens by Novel Computerized Analysis System
09:30 - 09:30 | Presenter: Akira Saito
- Abstract
Loading... -
+
P1.07-013 - Detection of Genomic Alterations in Plasma Circulating Tumor DNA in Patients with Metabolically Active Lung Cancers
09:30 - 09:30 | Author(s): Z. Yuan
- Abstract
Loading... -
+
P1.07-014 - Association of Preoperative Serum CRP with PD-L1 Expression in NSCLC: A Comprehensive Analysis of Systemic Inflammatory Markers
09:30 - 09:30 | Presenter: Takaki Akamine
- Abstract
Loading... -
+
P1.07-015 - Interferon-Gamma (INFG) as a Biomarker to Guide Immune Checkpoint Blockade (ICB) in Cancer Therapy
09:30 - 09:30 | Presenter: Niki Karachaliou
- Abstract
Loading... -
+
P1.07-016 - Comparison of PD-L1 Immunohistochemical Staining between EBUS-TBNA and Resected Non-Small Cell Lung Cancer Specimens
09:30 - 09:30 | Presenter: Kenneth Kazuto Sakata
- Abstract
Loading... -
+
P1.07-017 - Assessment of Cancer Immunity Status in Each Patient Using Immunogram
09:30 - 09:30 | Presenter: Takahiro Karasaki
- Abstract
Loading... -
+
P1.07-018 - A Meta-Analysis of PD-L1 Expression as a Biomarker of PD-1 Blockade in Advanced Non Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Johnathan Man
- Abstract
Loading... -
+
P1.07-019 - Immune Cell Infiltrates in Non-Small Cell Lung Cancer and Interleukin-22 Expression
09:30 - 09:30 | Author(s): J. Stump
- Abstract
Loading... -
+
P1.07-020 - Autoantibody Profiles of Cancer-Testis Genes in Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Dijana Djureinovic
- Abstract
Loading... -
+
P1.07-021 - Multiplex Immune Profiling Identifies Prognostic Importance of the Spatial Co-Localization of Immune Cells in NSCLC
09:30 - 09:30 | Presenter: Artur Mezheyeuski
- Abstract
Loading... -
+
P1.07-022 - Routine PD-L1 Immunohistochemistry Testing by 22C3 in a Canadian Reference Testing Centre
09:30 - 09:30 | Author(s): T. Albaqer
- Abstract
Loading... -
+
P1.07-023 - The Correlation Between B7-H4 Expression and Survival of Non-Small Cell Lung Cancer Patients Treated with Nivolumab
09:30 - 09:30 | Author(s): C. Genova
- Abstract
Loading... -
+
P1.07-024 - ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but
Not Chemotherapies or Targeted Kinase Inhibitors09:30 - 09:30 | Presenter: Wungki Park
- Abstract
Loading... -
+
P1.07-025 - Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients on Nivolumab
09:30 - 09:30 | Presenter: Wungki Park
- Abstract
Loading... -
+
P1.07-026 - Predicting Tumor Mutational Burden (TMB) and Tumor Neoantigen Burden (TNB) of East Asian ANSCLC Patients by a Targeted Genomic Profiling
09:30 - 09:30 | Presenter: Likun Chen
- Abstract
Loading... -
+
P1.07-027 - PD-L1 Expression Analysis in African American (AA) and Hispanic Lung Cancer Patients at a Minority-Based Academic Cancer Center
09:30 - 09:30 | Presenter: Elaine Shum
- Abstract
Loading... -
+
P1.07-028 - Determination of Soluble PD-L1 as a Potential Biomaker for Anti-PD(L)1 Therapy in Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Author(s): A. Barba Joaquín
- Abstract
Loading... -
+
P1.07-029 - Correlation Study Between Plasma sPD-L1 and the Efficacy and Prognosis of Patients with Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Xiaoyan Kang
- Abstract
Loading... -
+
P1.07-030 - Prognostic Impact of PD-L1 Expression in Correlation with HLA Class I Expression Status in Adenocarcinoma of the Lung
09:30 - 09:30 | Presenter: Kazue Yoneda
- Abstract
Loading... -
+
P1.07-031 - Autoantibodies Associated with Risk of Subclinical Autoimmunity and Immune-Related Adverse Events from Checkpoint Inhibitor Therapy
09:30 - 09:30 | Presenter: David E Gerber
- Abstract
Loading... -
+
P1.07-032 - 28-Color, 30 Parameter Flow Cytometry to Dissect the Complex Heterogeneity of Tumor Infiltrating T Cells in Lung Cancer
09:30 - 09:30 | Author(s): J. Brummelman
- Abstract
Loading... -
+
P1.07-033 - Differential Expression of Immune Inhibitory Markers in Association with the Immune Microenvironment in Resected Lung Adenocarcinomas
09:30 - 09:30 | Presenter: Mingjuan Lisa Zhang
- Abstract
Loading... -
+
P1.07-034 - Pretreatment Neutrophil & Platelet Count as a Predictor for Unfavorable Clinical Outcome in Non-Small Cell Lung Cancer (NSCLC)
09:30 - 09:30 | Presenter: Sarita Agte
- Abstract
Loading... -
+
P1.07-035 - Lymphocytes and Neutrophils Count After Two Cycles and TTF1 Expression as Early Outcome Predictors During Immunotherapy
09:30 - 09:30 | Presenter: Iosune Baraibar
- Abstract
Loading... -
+
P1.07-036 - LC-HRMS Metabolomics Profiling in Advanced NSCLC Treated with Anti PD-1 Agents. Metabolic Features at Diagnosis and at Response Evaluation
09:30 - 09:30 | Presenter: Ana Laura Ortega Granados
- Abstract
Loading... -
+
P1.07-037 - Testing the Positive and Negative Immune Checkpoint on PBMCs of Patients from Initiatory to Terminative Treatment of Anti PD-1 Antibody
09:30 - 09:30 | Presenter: Wushuang Du
- Abstract
Loading... -
+
P1.07-038 - The Potential Clinical Application of Comprehensive Genomic Profiling in Targeted Therapy and Immunotherapy of Lung Cancer
09:30 - 09:30 | Presenter: Mingwu Chen
- Abstract
Loading... -
+
P1.07-039 - Blood Biomarkers Correlate with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti PD-1 Antibodies
09:30 - 09:30 | Author(s): A.E. Soyano
- Abstract
Loading... -
+
P1.07-040 - Prognosis-Relevant Subgroups in NSCLC According to Granulocytic Myeloid-Derived Suppressor Cell Frequency and Cytokine Levels
09:30 - 09:30 | Author(s): Lourdes Barrera
- Abstract
Loading... -
+
P1.07-041 - CD47 Expression and Prognosis in a Cohort of Patients with Lung Adenocarcinoma (NSCLC)
09:30 - 09:30 | Presenter: Oscar Arrieta
- Abstract
Loading... -
+
P1.07-042 - PD-L1 and CD8 Expression in EGFR-Mutant or ALK-Rearranged Patients with Lung Cancer
09:30 - 09:30 | Author(s): S. Liu
- Abstract
Loading... -
+
P1.07-043 - Barrier Molecule Overexpression is Associated with Increased CD8 T Cells and Decreased B/Treg Cells in Human Lung Cancer
09:30 - 09:30 | Author(s): Young Kwang Chae
- Abstract
Loading... -
+
P1.07-044 - The Impact of Neutrophil/Lymphocyte Ratio as the Predictive Marker to Anti-PD-1 Antibody Treatment in NSCLC Patients
09:30 - 09:30 | Presenter: Keiko Tanimura
- Abstract
Loading... -
+
P1.07-044a - Comparison of Tumor Mutational Burden (TMB) Derived from Whole Exome and Large Panel Sequencing in Lung Cancer
09:30 - 09:30 | Author(s): G. Shan
- Abstract
No abstract available for this presentation
-
+
P1.07-044b - Pretreatment Neutrophil/Lymphocyte Ratio and the Efficacy of Nivolumab Treatment in Non–Small-Cell Lung Cancer
09:30 - 09:30 | Presenter: Hiroshi Kobayashi
- Abstract
Loading... -
+
P1.07-044c - Neurological Complications Following Treatment with Anti-PD1 Immune Checkpoint Inhibitors
09:30 - 09:30 | Author(s): R. Mason
- Abstract
Loading... -
+
P1.07-044d - Positive Conversion of the PD-L1 Expression after Treatments with Chemotherapy and Nivolumab
09:30 - 09:30 | Presenter: Naoki Haratake
- Abstract
Loading...
-
+
P1.08 - Locally Advanced NSCLC
- Type: Poster Session with Presenters Present
- Track: Locally Advanced NSCLC
- Presentations: 10
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.08-001 - Surgical versus Non-Surgical Treatments for Resectable Stage III NSCLC: A Systematic Review and Meta-Analysis
09:30 - 09:30 | Author(s): Y.Y. Soon
- Abstract
Loading... -
+
P1.08-002 - Blood Supply to the Tumor Do Not Predict the Effect of Induction Therapy in Patients with Locally Advanced Lung Cancer
09:30 - 09:30 | Presenter: Koji Kawaguchi
- Abstract
Loading... -
+
P1.08-003 - Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable, Stage III Non-Small Cell Lung Cancer: A Phase I Study
09:30 - 09:30 | Presenter: Kristin A Higgins
- Abstract
Loading... -
+
P1.08-004 - Adjuvant Chemoradiotherapy vs. Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Jong-Mu Sun
- Abstract
Loading... -
+
P1.08-005 - Preoperative Analysis of 18FDG-PET Features May Predict Loco-Regional Invasiveness in NSCLC
09:30 - 09:30 | Presenter: Pietro Bertoglio
- Abstract
Loading... -
+
P1.08-006 - Phase I/II Study of Carboplatin, nab-paclitaxel, and Concurrent Radiation Therapy for Patients with Locally Advanced NSCLC.
09:30 - 09:30 | Presenter: Yuko Kawano
- Abstract
Loading... -
+
P1.08-007 - Surgery versus Concurrent Chemoradiotherapy for Resectable CIIIA-N2 NSCLC: A Propensity Score Matched Analysis
09:30 - 09:30 | Presenter: Xin Sun
- Abstract
Loading... -
+
P1.08-008 - Chemoradiotherapy in the Regime of Accelerated Fractionation in the Treatment of Lung Cancer
09:30 - 09:30 | Author(s): D. Gogolin
- Abstract
Loading... -
+
P1.08-009 - Neutrophilia as Prognostic Biomarker in Locally Advanced Stage III Lung Cancer
09:30 - 09:30 | Author(s): A. Schernberg
- Abstract
Loading... -
+
P1.08-010 - Unsuspected N2 Disease in Patients Undergoing Surgery for Non-Small Cell Lung Cancer: Role of Extent and Location of the Lymph Node Metastasis
09:30 - 09:30 | Presenter: Saana Andersson
- Abstract
Loading...
-
+
P1.09 - Mesothelioma
- Type: Poster Session with Presenters Present
- Track: Mesothelioma
- Presentations: 13
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.09-001 - Multiplexed Biomarker Strategies Based on Targeted Proteomics for Detection of Malignant Pleural Mesothelioma in Blood
09:30 - 09:30 | Presenter: Ferdinando Cerciello
- Abstract
Loading... -
+
P1.09-002 - Cellular Noise and Positional Effects Determine the Cell Stem State in Malignant Mesothelioma
09:30 - 09:30 | Presenter: Walter Blum
- Abstract
Loading... -
+
P1.09-003 - Malignant Mesothelioma Versus Synovial Sarcoma: An Analysis of 19 Cases with Molecular Diagnosis
09:30 - 09:30 | Presenter: Sonja Klebe
- Abstract
Loading... -
+
P1.09-004 - YB-1 Suppresses miR-137 via a Feed Forward Loop, Increasing YB-1 Levels, Migration and Invasion in Malignant Mesothelioma
09:30 - 09:30 | Presenter: Karin Schelch
- Abstract
Loading... -
+
P1.09-005 - Targeting YB-1 Induces Either Drug Sensitisation or Resistance via Distinct Mechanisms in Malignant Pleural Mesothelioma
09:30 - 09:30 | Presenter: Thomas George Johnson
- Abstract
Loading... -
+
P1.09-006 - JMJ and BRD Domain Family Members in Malignant Pleural Mesothelioma: Potential Therapeutic Targets or Not?
09:30 - 09:30 | Presenter: Steven G. Gray
- Abstract
Loading... -
+
P1.09-007 - Targeting MET/TAM Receptors in Mesothelioma: Are Multi-TKIs Superior to Specific TKI?
09:30 - 09:30 | Presenter: Steven G. Gray
- Abstract
Loading... -
+
P1.09-008 - A 4-microRNA Signature in Serum Can Discriminate Between Non-Small-Cell Lung Cancer and Malignant Pleural Mesothelioma
09:30 - 09:30 | Presenter: Michaela B Kirschner
- Abstract
Loading... -
+
P1.09-009 - Evaluation of a Combined MicroRNA-Clinical Score as Prognostic Factor for Malignant Pleural Mesothelioma
09:30 - 09:30 | Presenter: Michaela B Kirschner
- Abstract
Loading... -
+
P1.09-010 - PD-L1 Reactivity of Tumor Cells Can Successfully Be Determined in Malignant Mesothelioma Effusions
09:30 - 09:30 | Author(s): M. Mansour
- Abstract
Loading... -
+
P1.09-011 - LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma
09:30 - 09:30 | Presenter: Anne Tsao
- Abstract
Loading... -
+
P1.09-012 - A Pre-Clinical Investigation of Intrapleural Curcumin Treatments as an Adjunct Therapy for Malignant Pleural Mesothelioma
09:30 - 09:30 | Presenter: Ashleigh Jean Hocking
- Abstract
Loading... -
+
P1.09-013 - Profiling Response to Chemotherapy in Malignant Pleural Mesothelioma Among Hispanics (MeSO-CLICaP)
09:30 - 09:30 | Presenter: Andrés F. Cardona
- Abstract
Loading...
-
+
P1.10 - Nursing/Palliative Care/Ethics
- Type: Poster Session with Presenters Present
- Track: Nursing/Palliative Care/Ethics
- Presentations: 7
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.10-002 - Outcome of Pilot RCT in Lung Cancer Surgery Patients Receiving Either Preop Carbohydrate & Postop Nutritional Drinks or Water
09:30 - 09:30 | Presenter: Amy Kerr
- Abstract
Loading... -
+
P1.10-003 - Synergy in Motion: Transferring Nursing Knowledge from Clinical Trials to Standard Therapy to Enhance Care and Communication
09:30 - 09:30 | Presenter: Dianne Zawisza
- Abstract
Loading... -
+
P1.10-004 - Testing Efficacy of a Pulmonary Rehabilitation Program for Post Lung Cancer Resection Surgery
09:30 - 09:30 | Presenter: Wei Ling Hsiao
- Abstract
Loading... -
+
P1.10-005 - Generation of Symptom Burden Patient-Reported Outcomes for Patients with Lung Cancer
09:30 - 09:30 | Author(s): L.A. Williams
- Abstract
Loading... -
+
P1.10-006 - Adverse Events After First-Line Target Therapy for Non-Small Cell Lung Cancer Patients in a Case Management Model
09:30 - 09:30 | Presenter: Lin Zhi Xuan
- Abstract
Loading... -
+
P1.10-007 - Preparing Mesothelioma Patients for Treatment: Providing Psychosocial Support Networks
09:30 - 09:30 | Presenter: Gleneara Elizabeth Bates
- Abstract
Loading... -
+
P1.10-008 - Palliative Care and Hospice Resources are Underutilized in Patients with Advanced Non-Small Cell Lung Cancer
09:30 - 09:30 | Presenter: Joshua Robert Rayburn
- Abstract
Loading...
-
+
P1.11 - Patient Advocacy
- Type: Poster Session with Presenters Present
- Track: Patient Advocacy
- Presentations: 4
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.11-001 - Economic Impact of Immune Checkpoint Inhibitor Therapy in Brazil and Strategies to Improve Access
09:30 - 09:30 | Presenter: Pedro Aguiar Jr
- Abstract
Loading... -
+
P1.11-002 - Lung Cancer in Nonagenarian Patients
09:30 - 09:30 | Presenter: Cheng Chieh Hsu
- Abstract
Loading... -
+
P1.11-003 - A Personalized Navigation Program to Increase Clinical Trial Participation of Lung Cancer Patients
09:30 - 09:30 | Author(s): A. Ciupek
- Abstract
Loading... -
+
P1.11-004 - Impact of Liquid Biopsy on the Treatment of Low-Income Lung Cancer Patients
09:30 - 09:30 | Author(s): A.A. D'Souza
- Abstract
Loading...
-
+